Literature DB >> 16989268

Mass vaccination for annual and pandemic influenza.

B Schwartz1, P Wortley.   

Abstract

Influenza virus causes annual epidemics and occasional pandemics. Frequent mutations in circulating influenza strains ("antigenic drift") result in the need for annual vaccination. More than two-thirds of persons in the U.S. are recommended for annual vaccination. Because influenza vaccine is available seasonally, mass vaccination strategies are well suited to its delivery. Although doctors offices are the most frequent setting for influenza vaccination overall, workplaces, clinics, and community sites (retail stores and pharmacies) also are common vaccination settings. Influenza vaccination also is delivered in mass vaccination clinics to health care workers and military personnel. Universal influenza vaccination, which has been recommended as a strategy to improve prevention by increasing vaccination coverage and providing indirect protection of adults by decreasing infection and transmission among children, would require expanded use of mass vaccination, for example in schools, as well as in the community. Influenza pandemics occur when a new influenza A subtype is introduced into the population ("antigenic shift"). Most or all of the population is susceptible to the pandemic virus and two doses of vaccine may be needed for protection. U.S. pandemic preparedness and response plans indicate that the entire population should be vaccinated beginning with defined priority groups including those who provide essential services including healthcare and those at highest risk of severe illness and death. Pandemic influenza vaccination will occur primarily through the public sector in mass clinic settings. Vaccination program planning must consider issues including coordination, staffing, clinic location and lay-out, security, record keeping, and communications. Exercising vaccination clinics is important for preparedness and can be done in the context of annual influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16989268     DOI: 10.1007/3-540-36583-4_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  14 in total

1.  Cost analysis of influenza vaccine administration in Fayette County, Kentucky, 2005-2007.

Authors:  Karen E Kryscio
Journal:  Public Health Rep       Date:  2010 Mar-Apr       Impact factor: 2.792

Review 2.  Immunosenescence of ageing.

Authors:  A L Gruver; L L Hudson; G D Sempowski
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

3.  A primer on strategies for prevention and control of seasonal and pandemic influenza.

Authors:  Scott Santibañez; Anthony E Fiore; Toby L Merlin; Stephen Redd
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

4.  Strategies for improving influenza immunization rates among hard-to-reach populations.

Authors:  David Vlahov; Micaela H Coady; Danielle C Ompad; Sandro Galea
Journal:  J Urban Health       Date:  2007-07       Impact factor: 3.671

5.  An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Authors:  Abylay R Sansyzbay; Marianna K Erofeeva; Berik M Khairullin; Nurlan T Sandybayev; Zhailaubay K Kydyrbayev; Seidigapbar M Mamadaliyev; Markhabat M Kassenov; Maria V Sergeeva; Julia R Romanova; Vera Z Krivitskaya; Oleg I Kiselev; Marina A Stukova
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

6.  2015 Pandemic Influenza Readiness Assessment Among US Public Health Emergency Preparedness Awardees.

Authors:  Thomas J Fitzgerald; Danielle L Moulia; Samuel B Graitcer; Sara J Vagi; Stephanie A Dopson
Journal:  Am J Public Health       Date:  2017-09       Impact factor: 9.308

Review 7.  Targeting the skin for microneedle delivery of influenza vaccine.

Authors:  Dimitrios G Koutsonanos; Richard W Compans; Ioanna Skountzou
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 8.  Prioritization of pandemic influenza vaccine: rationale and strategy for decision making.

Authors:  Benjamin Schwartz; Walter A Orenstein
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

9.  Project VIVA: a multilevel community-based intervention to increase influenza vaccination rates among hard-to-reach populations in New York City.

Authors:  Micaela H Coady; Sandro Galea; Shannon Blaney; Danielle C Ompad; Sarah Sisco; David Vlahov
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

Review 10.  Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature.

Authors:  Vincenza Gianfredi; Flavia Pennisi; Alessandra Lume; Giovanni Emanuele Ricciardi; Massimo Minerva; Matteo Riccò; Anna Odone; Carlo Signorelli
Journal:  Vaccines (Basel)       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.